Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579899 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
A Phase 2 study, sponsored by Evommune.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT05579899 is a Phase 2 study that has completed, run by Evommune. The registered enrollment target is 119 participants.
The verdict
NCT05579899, a Phase 2 study, has completed, sponsored by Evommune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
Interventions
- DRUG EVO101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05579899
The ClinicalTrials.gov registry entry for NCT05579899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evommune, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EVO101 is the first listed.
NCT05579899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05579899 about?
NCT05579899 is a clinical study titled "Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis". This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
What is the current status of trial NCT05579899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2022-09-27. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT05579899?
The interventions under investigation include: EVO101 (DRUG).
Who is sponsoring clinical trial NCT05579899?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.